Sign up to watch this video
Free access to all Sound Bites content
Dr. Andrew Kuykendall discusses disease modifying properties of interferon and defines how ropeginterferon is different from traditional interferon in terms of dosing and tolerability. (Video 3/3)
Published on: December 3, 2024
Medical Professional
Safety/Tolerability- How is ropeg different than regular interferon
Related Videos
Dr. Charu Aggarwal reviews safety highlights for datopotamab deruxtecan in pretreated mNSCLC (Video 2/3)
Charu Aggarwal, MD
Dr. Eric Singhi shows that PD-L1 expression is a spectrum in patients with aNSCLC (Video 2/3)
Eric Singhi , MD
Dr. Gregory Vidal discusses the safety, tolerability, and patient management techniques for inavolisib + palbociclib + fulvestrant in 1L PIK3CAm HR+, HER2- ABC (Video 2/2)
Gregory Vidal
Dr. Charu Aggarwal discusses the efficacy of datopotamab deruxtecan in pretreated mNSCLC (Video 1/3)
Charu Aggarwal, MD
Dr. Eric Singhi reviews 5-year efficacy of cemiplimab + chemotherapy in aNSCLC (Video 1/3)
Eric Singhi , MD
Dr. Joshua Zeidner reviews the data for revumenib in patients with NPM1-mutated AML (Video 3/3)
Joshua Zeidner, MD
IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America
© 2025 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.